Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance

Open Access

Peer-reviewed

Research Article

Eftychia Oikonomou,

Affiliation Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
⨯
Michal Koc,

Affiliation Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
⨯
Vladimira Sourkova,

Affiliation Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
⨯
Ladislav Andera,

Affiliation Laboratory of Cell Signaling and Apoptosis, Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
⨯
Alexander Pintzas

* E-mail: apint@eie.gr

Affiliation Laboratory of Signal Mediated Gene Expression, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
⨯

Reader Comments (0)

Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
HT29 cells
Is the Subject Area "HT29 cells" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Immunoprecipitation
Is the Subject Area "Immunoprecipitation" applicable to this article?

Thanks for your feedback.
MAPK signaling cascades
Is the Subject Area "MAPK signaling cascades" applicable to this article?

Thanks for your feedback.
Antibody therapy
Is the Subject Area "Antibody therapy" applicable to this article?

Thanks for your feedback.
Caco-2 cells
Is the Subject Area "Caco-2 cells" applicable to this article?

Thanks for your feedback.